ArticleJournal of oral and maxillofacial pathology : JOMFP
Galectin-1 expression in oral squamous cell carcinoma: An immunohistochemical study.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Galectins at the crossroads of tumor immunity, metabolism, and metastasis: mechanisms, therapeutic resistance, and translational opportunities.Frontiers in immunology · 2026Review
- Piezo1 promotes EMT and tumor progression in HNSCC through a YAP1-Associated Galectin-1 axis.Frontiers in cell and developmental biology · 2026Article
- Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: an insight into disease complexity, available therapies, and future considerations.Frontiers in immunology · 2025Review
- Prognostic significance of CD44s expression in oral squamous cell carcinoma: An immuno-histo-chemical analysis.Bioinformation · 2025Article
- Article
- Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextOral squamous cell carcinoma (OSCC) of the head and neck are a heterogeneous group of neoplasms with an increasing rate of mortality and morbidity. OSCCs are characterized by a high degree of local invasiveness and metastasis to cervical lymph nodes but show a lower rate of distant metastasis. Galectin-1 (Gal-1), a β-galactoside-binding lectin, is known to regulate tumor cell growth, angiogenesis, mediate cell-cell or cell-extracellular matrix adhesion and promote cancer cell migration.
aimsThis study aims to evaluate the Gal-1 expression in different clinical stages and histological grades of OSCC. SETTINGS AND
designForty histopathologically diagnosed cases of OSCC, including 16 cases of well-differentiated, 18 moderately differentiated and 6 poorly differentiated carcinomas, were included in the study group. MATERIALS AND
methodsThe samples were subjected to staining using primary mouse monoclonal antibodies against Gal-1 and visualized using polymer-HRP detection system. STATISTICAL ANALYSIS: The nonparametric Mann-Whitney U-test and Kruskal-Wallis ANOVA test were used for the statistical analysis.
resultsGal-1 expression was higher in advanced stages of OSCC, and the results were statistically significant. Immunoexpression of Gal-1 increased with advancing histological grades of OSCC with statistically significant results.
conclusionGal-1 plays an important role in invasion, metastasis and as a prognostic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.